Form 4: Pfizer CEO Acquires Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, acquired 24 phantom stock units under a deferred compensation plan.

Summary

• Albert Bourla, Chairman & CEO of Pfizer Inc. (PFE), acquired 24 phantom stock units.
• The acquisition occurred on August 15, 2025.
• Each unit was valued at $25.14.
• These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• The units are settled in cash following the reporting person's separation from service and may be transferred into an alternative investment account.
• Following this transaction, Mr. Bourla beneficially owns 730,477 phantom stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine executive compensation event, which is neutral in terms of immediate positive or negative implications for the company's operational or financial performance.

Positives

• Acquisition of phantom stock units by the Chairman & CEO indicates continued participation in the company's deferred compensation plan.

Future Outlook

Phantom stock units are designed to be settled in cash following the reporting person's separation from service and can be transferred into an alternative investment account at any time.

Industry Context

This filing details a routine insider transaction related to executive compensation, which is a common practice across various industries, including pharmaceuticals. It does not provide insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The acquisition of phantom stock units as part of a deferred compensation plan is a standard form of executive remuneration in large publicly traded companies, consistent with common industry practices for aligning executive interests with long-term company performance.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive compensation and holdings, which is a standard governance practice.
• Employees: Reflects the company's established executive compensation framework.

Next Steps

• Phantom stock units will be settled in cash following the reporting person's separation from service.

Key Dates

Recommendation

This Form 4 details a routine acquisition of phantom stock units by Pfizer's Chairman & CEO as part of a deferred compensation plan. Such transactions are common and do not typically indicate a significant change in the company's fundamental outlook or warrant a shift in investment strategy. The small number of units acquired relative to total holdings suggests no material impact on the stock's valuation or future performance, thus a 'hold' recommendation is appropriate as this filing does not present new information to alter an existing investment thesis.

Keywords

Pfizer, PFE, Albert Bourla, Form 4, SEC filing, phantom stock, deferred compensation, insider transaction, executive compensation